2020 Effect Of Sublingual Immunotherapy Tablet (SLIT-T) Treatment On Daily Medication Score Using Alternative Scoring Methods Based On WAO Recommendations

Saturday, 14 December 2013
Michigan Ballroom (Westin - Michigan Avenue)

Thomas Casale, MD , Creighton University, Omaha, NE

Hendrik Nolte, MD, PhD , Merck, Whitehouse Station, NJ

Jennifer Maloney, MD , Merck, Whitehouse Station, NJ

Amarjot Kaur, PhD , Merck, Whitehouse Station, NJ

Harold Nelson, MD , National Jewish Health, Denver, CO

Background: Efficacy of specific immunotherapy can be assessed by multiple means including effect on rescue medication use (daily medication score, or DMS). Trial designs have used different weighting models for rescue medication; the World Allergy Organization (WAO) has proposed standardized weighting to help facilitate comparison across studies.

Methods: Data from 5 randomized trials of sublingual immunotherapy tablet (SLIT-T) treatment for subjects with allergic rhinitis with or without conjunctivitis (AR/C) were analyzed (3 trials including standardized timothy grass SLIT-T, MK-7243 [Merck/ALK; 2800 BAU of Phleum pratense] and placebo; 2 ragweed trials including short ragweed SLIT-T, MK-3641 [Merck/ALK; 6 and 12 Amb a 1-U of Ambrosia artemisiifolia] and placebo). Approval was obtained from appropriate IRBs and informed consent obtained from all research subjects. As per protocols, all trials scored daily rescue medication use as follows: oral antihistamine, up to 6 pts; ocular antihistamine, up to 6 pts; intranasal corticosteroid, up to 8 pts; oral steroid, up to 16 pts. We analyzed DMS with adjusted weighting based on WAO recommendations, but including the medications used in per-protocol DMS: oral antihistamine, up to 1 pt; ocular antihistamine, up to 1 pt; intranasal corticosteroid, up to 2 pts; oral steroid, up to 3 pts. The primary analysis period was entire pollen season in grass trials and peak season in ragweed trials.

Results: The Table shows DMS by per-protocol and adjusted scoring methods. DMS was consistently reduced by grass and ragweed SLIT-T, by differences ranging from 26% (P=.084) to 45% (P=.0001) by per-protocol scoring and 26% (P=.078) to 47% (P<.0001) by adjusted scoring.

Conclusions: Grass and ragweed SLIT-T were associated with lower medication use vs placebo. Analysis of DMS as per the adjusted scoring methods based on WAO recommendations showed results similar to the per-protocol weighting.
Trial DMS (Per Protocol) Difference vs PBO in DMS (Per Protocol) P DMS (Adjusted) Difference vs PBO in DMS (Adjusted) P
P05238 (grass) PBO (n=207) 1.70 .27
2800 BAU  (n=184) 1.25 −.45 (−.96, .06); −26% .084 .20 −.07 (−.15, .01); −26% .078
P05239 (grass) PBO (n=158) 1.33 .21
2800 BAU (n=149) .91 −.42 (−.88, .03); −32% .066 .14 −.07 (−.14, .00); −33% .051
P08067 (grass) PBO (n=672) 1.36 .29
2800 BAU (n=629) .88 −.48 (−.73, −.22); −35% .0003 .18 −.10 (−.17, .04); −36% <.001
P05233 (ragweed) PBO (n=164) 2.87 .53
6 Amb a 1-U (n=150) 1.89 −.98 (−1.65, −.32); −34% .0039 .34 −.19 (−.32, −.07); −36% .0030
12 Amb a 1-U (n=159) 1.57 −1.30 (−1.95, −.64); −45% .0001 .28 −.25 (−.38, −.13); −47% <.0001
P05234 (ragweed) PBO (n=169) 3.09 .58
6 Amb a 1-U (n=167) 2.01 −1.08 (−1.84, −.32); −35% .0053 .37 −.21 (−.36, −.06); −37% .0050
12 Amb a 1-U (n=152) 1.99 −1.10 (−1.89, −.32); −36% .0058 .37 −.21 (−.36, −.06); −36% .0076